---
figid: PMC5443413__nihms811799f4
figlink: /pmc/articles/PMC5443413/figure/F4/
number: F4
caption: Mechanism of resistance and SCC development. BRAFV600E inhibition via vemurafenib
  induces paradoxical activation of MAPK through increased CRAF activity and acquired
  NRAS mutation. In addition, increased PDGFRb expression with subsequent activation
  of PI3K/AKT pathway for increased resistance. It is hypothesized that these reported
  mechanisms are shared in drug resistance as well as cutaneous squamous cell carcinoma
  development.
pmcid: PMC5443413
papertitle: The discovery of vemurafenib for the treatment of BRAF-mutated metastatic
  melanoma.
reftext: Alex Kim, et al. Expert Opin Drug Discov. ;11(9):907-916.
pmc_ranked_result_index: '75050'
pathway_score: 0.9247447
filename: nihms811799f4.jpg
figtitle: Mechanism of resistance and SCC development
year: ''
organisms:
- Homo sapiens
ndex: 84c0643e-deb1-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5443413__nihms811799f4.html
  '@type': Dataset
  description: Mechanism of resistance and SCC development. BRAFV600E inhibition via
    vemurafenib induces paradoxical activation of MAPK through increased CRAF activity
    and acquired NRAS mutation. In addition, increased PDGFRb expression with subsequent
    activation of PI3K/AKT pathway for increased resistance. It is hypothesized that
    these reported mechanisms are shared in drug resistance as well as cutaneous squamous
    cell carcinoma development.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - RAF1
  - MAP2K2
  - MAPK1
  - MAPK3
  - AKT2
  - PIK3CA
  - MAP2K1
  - AKT1
  - SERPINB3
  - PIK3R3
  - PIK3R4
  - AKT3
  - PIK3CD
  - PIK3CG
  - MTOR
  - PIK3CB
  - PIK3R6
  - PIK3R5
  - PDGFRB
  - Cancer
genes:
- word: CRAF
  symbol: c-Raf
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: SCC
  symbol: SCC
  source: hgnc_prev_symbol
  hgnc_symbol: SERPINB3
  entrez: '6317'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PDGFRB
  symbol: PDGFRB
  source: hgnc_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC5443413__F4
redirect_from: /figures/PMC5443413__F4
figtype: Figure
---
